Creative Biolabs, a biotechnology service provider specializing in immuno-oncology research, has announced an exclusive webinar titled "Modeling T Cell Dysfunction in Tumor Microenvironments," scheduled for September 1, 2026, at 10:00 AM EDT. The live virtual event will feature a keynote presentation by Greg M. Delgoffe, Ph.D., a renowned expert in immunology and Director of the Tumor Microenvironment Center at the UPMC Hillman Cancer Center.
The webinar addresses a critical challenge in oncology: understanding the tumor microenvironment (TME) and its role in immune evasion. The TME is a complex ecosystem where cancer cells, immune cells, and metabolites interact. As tumors progress, they create a metabolically hostile environment characterized by nutrient depletion and accumulation of immunosuppressive byproducts. These metabolic pressures impair immune cell function, leading to T cell dysfunction, immune evasion, and reduced responses to standard cancer immunotherapies.
Traditional models often fail to capture the nuanced interactions between tumor metabolism and immune regulation. By utilizing advanced preclinical testing services and robust in vivo and in vitro models, researchers can better replicate these metabolic stress conditions. These advanced systems provide valuable tools to investigate immune suppression and therapeutic responses under physiologically relevant conditions.
"Understanding how metabolic conditions within tumors influence immune-cell behavior is increasingly important in immuno-oncology," said a senior scientific director at Creative Biolabs. "Dr. Delgoffe's work provides an important perspective on how researchers can model these conditions and investigate target discovery and validation."
The webinar will cover key topics including how tumor metabolic environments contribute to immune suppression and T cell exhaustion, strategies for modeling TME conditions in preclinical research systems, the mechanisms underlying T cell exhaustion and how nutrient depletion influences T cell function, and how immunometabolism insights can guide therapeutic strategies to enhance cancer immunotherapy.
This event is particularly relevant for cancer immunology researchers, pharmaceutical and biotechnology professionals, and R&D teams dedicated to oncology drug discovery. The implications are significant: by better understanding T cell dysfunction in the TME, researchers can develop more effective immunotherapies and improve patient outcomes.
For webinar details and registration, visit the official webinar page.
